In the 1990s, the first AChE inhibitors were introduced to therapy (tacrine-1993 and donepezil-1996), followed by others in the following years (rivastigmine-2000 and galantamine 2001), and are used (except tacrine, which was withdrawn in 2013) as key drugs in the treatment of AD [6]. The gene discussed is ACHE; the disease is Alzheimer disease.